Lars Nieba | CEO
Engimmune Therapeutics AG

Lars Nieba brings more than 25 years of leadership experience in the development of several pharmaceutical products and innovative technologies. He most recently was CTO and CEO at Nordic Nanovector, a biotech company developing novel radio-immunoconjugates for treating cancers. Previously, Lars was VP and Strategic Product Lead at Bayer. Before that he held several leadership roles at F. Hoffmann-La Roche in clinical operations, clinical supply planning, biologics technology and business development. Lars gained his PhD from the Max-Planck-Institute for Biochemistry, Munich, and Institute for Biochemistry at the University of Zurich; he also holds an executive MBA from the University of St. Gallen, Switzerland.